Browsing by Author Wu, Yi-long

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2015Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsBoyer, Michael; Bennouna, Jaafar; Feng, Jifeng; Geater, Sarayut; Gorbunova, Vera; Hirsh, Vera; Hu, Cheng-Ping; Huang, Yunchao; Kato, Terufumi; Lee, Ki Hyeong; Lee, Kye Young; Lu, Shun; Massey, Dan; Mok, Tony; O'Byrne, Kenneth; Orlov, Sergey; Popat, Sanjay; Schuler, Martin; Sebastian, Martin; Sequist, Lecia; Shahidi, Mehdi; Su, Wu-Chou; Tsai, Chun-Ming; Wu, Yi-long; Yamamoto, Nobuyuki; Yang, James Chic-Hsin; Zazulina, Victoria; Zhou, Caicun; Central Clinical School: MedicineAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncology, vol.16, 2, 2015,pp 141-151
2017Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survivalDavies, Lucy; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Marschner, Ian; Fukuoka, Masahiro; Gralla, Richard J; Inoue, Akira; Mitsudomi, Tetsuya; Mok, Tony; Nakagawa, Kazuhiko; Rosell, Rafael Costa; Thongprasert, Sumitra; Tu, Yu-Kang; Wu, Yi-long; Yang, James; Zhou, Caicun; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreGefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival, Journal of the National Cancer Institute, vol.109, 6, 2017,pp 1-13
2015Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-AnalysisDing, Pei Ni; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Pavlakis, Nick; Gralla, Richard J; Inoue, Akira; Links, Matthew; Mitsudomi, Tetsuya; Rosell, Rafael Costa; Wu, Yi-long; Yang, James Chic-Hsin; Zhou, Ci-Xiang; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: MedicineImpact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, Journal of Clinical Oncology, vol.33, 17, 2015,pp 1958-1965
2017Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerLee, Chee Khoon; Ahn, Myung-Ju; Akamatsu, Hiroaki; et al, Various; Garassino, Marina; He, Yong; Kim, Hye; Mok, T. S. K.; Ramalingam, Suresh; Shepherd, Frances; Wu, Yi-long; NH&MRC Clinical Trials CentreOsimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, New England Journal of Medicine, vol.376, 7, 2017,pp 629-640
2017The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCvan Zandwijk, Nico; Brustugun, Odd Terje; Dingemans, Anne-Marie; et al, Various; Grey, Jhanelle; Manegold, C; Nakagawa, Kazuhiko; Nicolson, Marianne; Peters, Solange; Reck, Martin; Wu, Yi-long; Concord Clinical School: MedicineThe Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC, Journal of Thoracic Oncology, vol.12, 2, 2017,pp 194-207
2010Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 studyPavlakis, Nick; Crino, Lucio; Dansin, Eric; Garrido, Pilar; Griesinger, Frank; Laskin, Janessa; Stroiakovski, Daniel; Thatcher, N; Tsai, Chun-Ming; Wu, Yi-long; Zhou, Caicun; Northern Clinical School: MedicineSafety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study, Lancet Oncology, vol.11, 8,pp 733-740
2011Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.van Zandwijk, Nico; Heigener, David; Horwood, Keith; Mali, Pekka; Reck, Martin; Wu, Yi-long; Concord Clinical School: ANZAC Research InstituteSecond-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study., Lung cancer, vol.74, 2, 2011,pp 274-279